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Abstract: Hot flashes are one of the most common and distressing symptoms associated 
with menopause, occurring in more than 75% of postmenopausal women. They are especially 
problematic in breast cancer patients since some breast cancer therapies can induce hot flashes. 
For mild hot flashes, it is proposed that behavioral modifications are the first step in management. 
Hormonal therapies, including estrogens and progestogens, are the most well known effective 
agents in relieving hot flashes; however, the safety of these agents is controversial. There is an 
increasing amount of literature on nonhormonal agents for the treatment of hot flashes. The 
most promising data regard newer antidepressant agents such as venlafaxine, which reduces 
hot flashes by about 60%. Gabapentin is another nonhormonal agent that is effective in reduc-
ing hot flashes. While many complimentary therapies, including phytoestrogens, black cohosh, 
and dehydroepiandrosterone, have been explored for the treatment of hot flashes; none can be 
recommended at this time. Furthermore, there is a lack of strong evidence to support exercise, 
yoga, or relaxation for the treatment of hot flashes. Paced respirations and hypnosis appear to 
be promising enough to warrant further investigation. Another promising nonpharmacological 
therapy, currently under investigation, involves a stellate ganglion block.
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Introduction
Menopause, an expected event in a woman’s life, is commonly defined as 12 months of 
amenorrhea. This transition often begins in the late 40s, with a median age of 51  years.1 
Menopause is associated with multiple symptoms including vasomotor symptoms, 
vaginal symptoms, urinary incontinence, sexual dysfunction, and trouble sleeping.
One of the most common and distressing symptoms of menopause are hot flashes. Hot 
flashes occur in over 75% of menopausal women.2,3 Women often describe these episodes 
as recurrent periods of flushing, sweating, and an intense heat that begins on the face and 
upper chest. Hot flashes can also be associated with a feeling of anxiety, palpitations, and 
red blotching of the skin.3,4 These episodes usually last for 2–4 minutes and can vary in 
frequency, with some women experiencing episodes multiple times per day, while others 
experience them as infrequently as once a month. Although not life-threatening, hot flashes 
can have a detrimental effect on a woman’s functional ability and quality of life.5
Hot flashes are especially problematic in breast cancer patients. Multiple 
preventative and treatment strategies for breast cancer can induce hot flashes, including 
anti-estrogenic medications, oophorectomy, and certain forms of chemotherapy.6,7 
In addition, it has been reported that breast cancer survivors have more frequent and 
severe hot flashes than women who undergo normal menopause.8 International Journal of Women’s Health 2010:2 submit your manuscript | www.dovepress.com
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The purpose of this article is to review the evidence for 
and against the current available treatments for hot flashes.
Etiology
The mechanism behind hot flashes is not completely 
understood. It has long been believed that hot flashes 
result from the decrease in estrogen levels associated with 
menopause. During menopause, the number of ovarian 
follicles and the production of estrogen decreases. Hot flashes 
seem to occur synchronously with these changes.9 However, 
the exact role of estrogens in the mechanism of hot flashes 
is unclear. There is research to support the hypothesis that 
it is the estrogen withdrawal, not low levels of estrogen 
that leads to hot flashes. For example, women with gonadal 
dysgenesis, who have consistently low levels of estrogen, 
do not experience hot flashes unless they are given estrogen 
replacement therapy, which is later discontinued. Also, 
women who experience abrupt estrogen withdrawal, such as 
from oophorectomy, have a rapid onset of hot flashes.10,11 In 
addition, hot flashes are often more prevalent at the beginning 
of menopause and do not usually continue throughout the 
postmenopausal time when circulating estrogens are low.11
The perspiration and vasodilatation associated with hot 
flashes appears to be controlled by the thermoregulatory 
nucleus, which is located in the preoptic area of the 
hypothalamus. The thermoregulatory nucleus regulates core 
body temperature and works to keep it within a homeostatic 
range called the thermoregulatory zone.10 Hot flashes are 
triggered if body temperatures are elevated or sweating 
thresholds are lowered.12 Women who suffer from hot flashes 
appear to have a thermoregulatory zone that is narrower and 
thus small increases in core body temperature can trigger 
hot flashes.13
Norepinephrine and serotonin may be involved in the 
complex neuroendocrine pathway controlling the thermo-
regulatory zone.9 It is proposed that elevated brain norepi-
nephrine narrows the thermoregulatory zone.12 In addition, 
there has been increased interest in the role of serotonin in the 
hot flash mechanism. Activation of specific serotonin recep-
tors can cause hypothermia or hyperthermia.14 Estrogen 
withdrawal is associated with decreasing levels of serotonin 
and an increase in serotonin receptors in the hypothalamus.9,11 
In one proposed model for the pathogenesis of hot flashes 
estrogen withdrawal leads to a decrease in endorphin and 
catecholestrogen levels. This in turn leads to increased 
norepinephrine and serotonin release, which lowers the set 
point in the thermoregulatory nucleus, thus increasing the 
likelihood of hot flashes.9
Treatment of hot flashes
Hormonal therapies
estrogen replacement
Estrogen replacement is the most effective treatment for 
reducing hot flashes, with reductions of more than 75% in 
frequency.15–17 Unfortunately, there are many situations in 
which estrogen therapy is contraindicated. The Women’s 
Health Initiative (WHI) trial reported that the overall health 
risks of long-term estrogen therapy; including increased 
risk of venothrombotic disease, breast cancer, stroke, and 
coronary artery disease, exceed the benefits.18 However, hor-
mone therapy is still approved for the treatment of moderate 
to severe vasomotor symptoms.17 When hormonal treatment 
is utilized for treating hot flashes, it is generally accepted 
that it should be used at the lowest dose and for the shortest 
effective length of time.17,19
More recent literature has investigated short-term 
and low dose estrogens for the treatment of vasomotor 
symptoms. A double-blind, placebo-controlled trial was 
undertaken to investigate the efficacy of micro-dose transder-
mal estrogen for relief of hot flashes. Women used transdermal 
patches with low dose estrogen (0.023 mg/d 17β-estradiol 
and 0.0075 mg/day levonorgestrel), micro-dose estrogen 
(0.014 mg/day 17β-estradiol) or placebo. Women using the 
micro-dose estrogen had a significant reduction in hot flashes 
when compared to placebo with 41% of patients having a 
reduction in hot flashes of 75% or more.20 Another study evalu-
ated the efficacy of low dose estradiol gel for the treatment 
of hot flashes. Women received estradiol gel 0.1% at doses 
of 1.0, 0.5, and 0.25 mg/day. All three doses demonstrated 
a statistically significant reduction in the frequency of hot 
flashes, but these reductions were dose dependent.21 Currently, 
0.0125 mg/day dose of Elestrin is the lowest effective dose 
of estradiol gel approved for the treatment of hot flashes.22 
Studies have shown that low dose estrogen may be less likely 
to cause many of the serious complications associated with 
higher dose estrogen.19,20 However, the risks associated with 
long-term use of low dose estrogens are still unknown since 
this has not been evaluated in clinical trials.19,22
The use of estrogen therapy in breast cancer survivors is 
also a controversial topic. While some literature suggests that 
estrogen therapy might be safe in breast cancer survivors,6 
the current sentiment of most clinicans is to avoid the use of 
estrogen in this population.17,23
Progestational agents
The North American Menopause Society determined that the 
primary menopausal-related indication for progesterone use is International Journal of Women’s Health 2010:2 submit your manuscript | www.dovepress.com
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to negate the increased risk of endometrial cancer from sys-
temic estrogen therapy. Therefore, the recommendation is that 
all women with an intact uterus requiring hormonal therapy for 
menopausal symptoms should be prescribed progesterone.17,24 
However, in recent years, there have been several trials that 
have shown progestational agents to be a reasonable alternative 
to estrogen, for the treatment of vasomotor symptoms.
Megestrol acetate was found to be effective in reducing 
hot flashes in a double-blind, placebo-controlled, randomized 
clinical trial that included 97 women with a history of breast 
cancer and 66 men receiving androgen deprivation therapy 
for prostate cancer. Patients receiving megestrol acetate, 
at a dose of 40 mg per day, showed an 85% reduction in 
hot flashes, as compared to a 21% reduction in the placebo 
group.25 A substantial proportion of patients in this trial 
continued to use megestrol acetate for periods of up to 3 years 
or longer, with continued control of hot flashes.26 In addition, 
a daily megestrol acetate dose of 20 mg appears to be equally 
efficacious to a 40 mg daily dose.27
Medroxyprogesterone acetate (MPA), a similar medication, 
comes in both oral and intramuscular forms, both of which 
have been shown to decrease menopause related hot flashes. 
Multiple, double-blind, placebo-controlled trials, performed in 
the 1970s and 1980s, found intramuscular depomedroxypro-
gesterone acetate (DMPA) to be efficacious in reducing hot 
flashes.28–30 A more recent randomized, placebo-controlled 
clinical trial was undertaken to compare DMPA with megestrol 
acetate in postmenopausal women with a history of breast 
cancer; they found both agents to have similar efficacy with 
a reduction of 86%, on average, in both groups.31 In addition, 
an observational study of 15 women with a history of breast 
cancer reported that hot flashes were reduced by 90% in women 
receiving DMPA.32 Another randomized controlled trial dem-
onstrated that DMPA and conjugated equine estrogen were 
equivalent in their efficacy at reducing hot flashes in patients 
who underwent hysterectomy/ovariectomy.33
The role of progesterone cream for the treatment of hot 
flashes is controversial. One randomized placebo-controlled 
trial of a progesterone cream in healthy postmenopausal 
women found a significant reduction in hot flashes, 83% 
compared to 19% in the placebo group.34 However, a 
recent double-blind, placebo-controlled trial of progestelle 
progesterone cream in 223 healthy postmenopausal women 
found no statistically significant difference between the treat-
ment group and placebo.35
Despite the efficacy of progestational agents in the 
treatment of hot flashes, it can be associated with similar 
side effects as estrogen, and therefore it is contraindicated 
in women with thromboembolic disorders, impaired liver 
function, and undiagnosed uterine bleeding.24 The role of 
progestational agents in women with a history of breast 
cancer is still unclear. This is partially because it has been 
proposed that progestational agents may stimulate tumor 
growth.36 An epidemiological study failed to find any increase 
in breast cancer risk in women who used progesterone alone.37 
Overall, the data on the association between progesterone 
and increased breast cancer risk is still controversial and to 
date no reliable conclusion can be made.24
Tibolone
Tibolone is a synthetic steroid that has both a weak estro-
genic, progestagenic, and androgenic action.38 It is proposed 
that tibolone has tissue specific activity which is the result of 
metabolism, enzyme regulation, and receptor activation that 
vary in different tissues.39,40 Tibolone has been used for almost 
20 years in Europe for the treatment of vasomotor symptoms, 
but is not available in the United States.19 A double-blind, 
randomized controlled trial of 437 postmenopausal women 
found that treatment with tibolone significantly reduced the 
mean scores for hot flashes and was comparable to estrogen 
therapy.41 The most common adverse effects were weight gain 
and bloating.38 However, the Million Women Study suggested 
that tibolone increased the risk of breast cancer.42 In addition, 
the Liberate trial showed that women with a history of breast 
cancer had increased recurrence of cancer if they were taking 
tibolone.43 On the other hand, a trial investigating the use of 
tibolone in postmenopausal women with low bone density 
found that the women using tibolone had a decrease in breast 
cancer events.44 One explanation for these various findings may 
be that tibolone affects healthy breast tissue differently than it 
does cancer cells.43 Additional research is needed to investigate 
the effect of tibolone on the risk of breast cancer in healthy 
postmenopausal women.45 At this time, tibolone should not be 
used in breast cancer patients, and should be used with caution 
in the general postmenopausal population.
Non-hormonal therapy
Many patients and physicians feel that the risks associated 
with hormonal therapy outweigh the therapeutic benefit. Con-
sequently, nonhormonal therapies for hot flashes have received 
a significant amount of attention over the past 20 years.
Centrally acting compounds
Bellergal
Bellergal is a combination product of belladonna alkaloids 
and phenobarbital. It was used in the 1970s and 1980s as  International Journal of Women’s Health 2010:2 submit your manuscript | www.dovepress.com
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a treatment for hot flashes. A placebo-controlled trial of 
66 healthy women tested Bellergal Retard against placebo. 
The group of patients taking Bellergal had a decrease in the 
number of hot flashes by 75%, versus 68% in the placebo 
group. This small improvement was not significant.46 
Another study which included 50 patients demonstrated that 
patients taking Bellergal reported a moderate improvement 
in hot flashes over placebo.47 Adverse effects associated 
with Bellergal included dry mouth, dizziness, rash, and 
sleepiness. Due to the moderate efficacy and the availability 
of safer therapies, Bellergal is not recommended for the 
treatment of hot flashes.
Clonidine
Clonidine is a centrally acting α-adrenergic agonist that was 
first proposed as a treatment for hot flashes in the 1970s.48–50 
One proposed mechanism of action in the treatment of hot 
flashes is that clonidine raises the sweating threshold by reduc-
ing norepinephrine release.51 A randomized, double-blind, 
controlled trial was performed using a 0.1 mg transdermal 
clonidine patch versus placebo in 110 women with a his-
tory of breast cancer. Patients receiving clonidine had an 
additional 20% reduction in hot flashes, as compared to 
the placebo group. However, patients experienced sig-
nificant adverse effects including mouth dryness, consti-
pation, itchiness, and drowsiness.52 Another randomized 
controlled trial evaluated the efficacy of oral clonidine in 
149 postmenopausal women with breast cancer receiving 
tamoxifen therapy. After 8 weeks of treatment, the mean 
decrease in hot flash frequency was 38%, as compared to 
24% in the placebo group. Again, patients reported significant 
side effects, including difficulty sleeping.53 A recent meta-
analysis included 10 trials of clonidine for the treatment of 
hot flashes and found inconsistent results, with half of the 
trials showing that clonidine was effective in treating hot 
flashes.54 Despite some positive results in these trials, the 
use of clonidine for hot flash treatment is not recommended 
because of significant side effects.
Methyldopa
Methyldopa is an antihypertensive agent that has been 
investigated as a treatment for hot flashes. A double-blind, 
placebo-controlled study was undertaken involving 
postmenopausal women, and demonstrated that 250 mg of 
methyldopa was more effective than placebo at decreasing 
hot flashes. There was a 30% to 37% reduction in frequency 
of hot flashes in the methyldopa group, as compared to a 10% 
to 20% reduction in the placebo group. Adverse reactions 
including dizziness, nausea, and fatigue, occurred in 50% 
of the patients.55 Therefore, due to its significant adverse 
affects, methyldopa is not recommended as a therapy for 
hot flashes.
veralipride
Veralipride is a benzamide derivative with antidopaminergic 
effects, which has been studied as a treatment of hot flashes. 
A double-blind, randomized controlled study in 43 women 
compared treatment with veralipride to conjugated estrogens 
for the treatment of hot flashes. No significant difference 
in effectiveness or tolerance was found between the two 
treatments.56 Another trial tested veralipride versus placebo 
in healthy postmenopausal women. In this study, veralipride 
was associated with a significant reduction in hot flashes.57 
Adverse effects of veralipride included breast tenderness, 
galactorrhea, gastrointestinal complaints, and dyspnea.58,59 
Veralipride has also been associated with extraparamidal 
disorders, including acute dyskinesia and Parkinsonism.60 
Due to its toxicities, veralipride is not approved for use in 
the United States and is currently not recommended for the 
treatment of hot flashes.
Newer antidepressants
In the 1990s it was recognized that women taking selective 
serotonin reuptake inhibitors (SSRI) had a decrease in 
hot flashes.9 As a result of these observations, it was 
hypothesized that such antidepressants may have a therapeutic 
effect on hot flashes. Since this time multiple randomized, 
placebo-controlled clinical trials have been undertaken to 
test this hypothesis, using several different agents. Overall, 
the results have been promising.
venlafaxine
Venlafaxine selectively inhibits reuptake of serotonin, norepi-
nephrine, and dopamine. Venlafaxine was first studied as a 
treatment for hot flashes in 1998 in a pilot trial which included 
28 patients. This pilot trial involved both women with a history 
of breast cancer and men with prostate cancer who received 
androgen-deprivation therapy. The majority of patients reported 
a greater than 50% reduction in median hot flash scores after 
four weeks of treatment with venlafaxine, 12.5 mg twice daily. 
In addition, treatment with venlafaxine also seemed to allevi-
ate other symptoms, including fatigue, sweating, and trouble 
sleeping. At the completion of the study, 64% of patients chose 
to continue treatment with venlafaxine.61
The same group conducted a placebo-controlled, 
randomized clinical trial in order to further evaluate the International Journal of Women’s Health 2010:2 submit your manuscript | www.dovepress.com
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efficacy of venlafaxine for hot flashes. This study included 
191 women who were assigned to a placebo or to target ven-
lafaxine doses of 37.5 mg daily, 75 mg daily, or 150 mg daily. 
All venlafaxine treatment started at 37.5 mg daily and gradu-
ally increased to the desired goal dose. After 4 weeks of treat-
ment, hot flash scores reduced from baseline by 27%, 37%, 
61%, and 61%, respectively, in the four groups. Although the 
75 mg/d dose had a greater effect than the 37.5 mg/d dose, 
150 mg/d was not superior to 75 mg/day. In fact the 150 mg 
daily group had more side effects, including mouth dryness, 
decreased appetite, nausea, and constipation.62
Another randomized controlled trial of venlafaxine 
was performed in 80 postmenopausal women. Patients 
were randomized to receive extended-release venlafaxine 
at 37.5 mg daily for 1 week, followed by 75 mg daily for 
11 weeks or placebo. In this trial, subjective assessments 
of hot flash symptoms on daily living were significantly 
improved in the treatment group.63 However, this trial did not 
collect any baseline hot flash data, which makes it difficult 
to interpret.
A more recent randomized controlled trial was undertaken 
comparing venlafaxine to DMPA in the management of hot 
flashes. This trial involved 109 women who were randomly 
assigned to receive DMPA 400 mg intramuscularly as a single 
dose or venlafaxine 37.5 mg daily for a week, then 75 mg 
daily. After 6 weeks of treatment, there was a 55% reduction 
in hot flash score in the venlafaxine group, versus a 79% 
reduction in the DMPA group. In addition, less short-term 
toxicity was reported in the DMPA group.64 However, the 
safety of progesterone for treatment of hot flashes, especially 
in breast cancer patients remains controversial and this should 
be discussed with a patient prior to starting therapy.
Desvenlafaxine
Desvenlafaxine is a new serotonin norepinephrine reuptake 
inhibitor (SNRI) and is the succinate salt form of the major 
active metabolite of venlafaxine.65 Since venlafaxine was 
found to be successful in relieving hot flashes, it was 
hypothesized that desvenlafaxine may have a similar effect. 
A randomized, double-blind, placebo-controlled trial, includ-
ing 707 healthy postmenopausal women, was undertaken 
to test this hypothesis. Women were randomized to receive 
desvenlafaxine 50 mg, 100 mg, 150 mg, 200 mg, or placebo 
daily. There was no significant difference in hot flashes 
between the 50 mg group (55%) and placebo (51%). However, 
there were significant reductions in the 100 mg, 150 mg, and 
250 mg daily groups, with reductions of 64%, 60%, and 60%, 
respectively. The most common adverse drug reaction was 
nausea, which was dose-dependent.66 Another randomized, 
double-blind, placebo-controlled trial of desvenlafaxine for 
the treatment of hot flashes included 567 postmenopausal 
women who were assigned to receive desvenlafaxine 100 mg 
or 150 mg daily or placebo. After 12 weeks, reductions in the 
number of hot flashes in the 100 mg, 150 mg, and placebo 
group were 60%, 66%, and 47%, respectively.67
Paroxetine
Paroxetine, an SSRI, was first explored as a treatment for hot 
flashes in a pilot trial conducted in 2000. The trial included 
30 women with a history of breast cancer who received 
10 mg of paroxetine daily for one week followed by four 
weeks of 20 mg daily. There was a significant reduction 
from baseline in hot flash frequency and score; 67% and 
75%, respectively. In addition, there were improvements in 
depression, sleep, anxiety and quality of life scores.68 Based 
on these promising findings, a randomized controlled trial 
of paroxetine for the treatment of hot flashes was under-
taken. This trial included 156 menopausal women who 
were randomized to receive paroxetine at 12.5 mg daily, 
25 mg daily, or placebo. After 6 weeks of treatment there 
was a 62% reduction in hot flash score in the 12.5 mg daily 
group, 65% reduction in the 25 mg daily group, and a 38% 
reduction in placebo group. The most frequently reported 
side effects with paroxetine were headache, nausea, and 
insomnia.69 Another randomized, double-blind, cross-over, 
placebo-controlled trial involved 151 women who were 
assigned to receive 4 weeks of 10 mg or 20 mg of paroxetine 
followed by placebo, or placebo for 4 weeks followed by 
paroxetine 10 mg or 20 mg. Paroxetine 10 mg was found 
to reduce hot flash frequency by 40.6% compared to 13.7% 
with placebo. Paroxetine 20 mg daily reduced the frequency 
by 51.7% compared to 26.6% with placebo. Overall, both 
doses of paroxetine had similar efficacy but the 10 mg daily 
was better tolerated.70
Fluoxetine
Based on the positive results of previous trials of newer 
antidepressants and anecdotal information regarding the 
efficacy of fluoxetine in the treatment of hot flashes, a 
double-blind, randomized, cross-over study was performed. 
This trial included 81 women who were assigned to either 
fluoxetine 20 mg daily or placebo, after 4 weeks the groups 
switched. After the first treatment period, there was a 50% 
decrease in hot flash scores in the fluoxetine group versus a 
36% reduction in placebo group. The cross-over analysis also 
found the fluoxetine group to have a greater reduction in hot  International Journal of Women’s Health 2010:2 submit your manuscript | www.dovepress.com
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flash score. There were no statistically significant toxicities 
experienced in treatment groups.71
Another randomized, placebo-controlled, study 
compared the efficacy of citalopram to fluoxetine in the 
treatment of hot flashes. This trial included 150 women who 
were randomized into three groups: placebo, fluoxetine, 
or citalopram. Fluoxetine and citalopram were started at 
10 mg and then increased to 20 mg at one month, and 
30 mg at 6 months. The authors reported no statistically 
significant differences in the numbers of hot flashes between 
all groups.72 However, instead of collecting baseline hot 
flash data prior to initiation of the study treatments, the 
investigators used the first day of treatment as a baseline.73 
This is problematic, because antidepressants can have a 
significant immediate effect on decreasing hot flashes. In 
fact, a 31% reduction in hot flashes was seen in the first day 
of treatment with venlafaxine.73 Thus, the reported results 
of this trial are suspect.
Citalopram
Citalopram was first tested as a treatment for hot flashes in a 
pilot trial in 2003, which involved 26 women with a history 
of breast cancer. After 4 weeks of treatment at 10 mg daily 
for the first week and 20 mg daily for the following weeks, 
patients had a decrease in hot flash frequency by 58%.74 
Another pilot trial evaluated the efficacy of citalopram for 
hot flash treatment in 22 patients who had inadequate relief 
while taking venlafaxine. After 4 weeks of treatment, hot flash 
scores were reduced by 53%. Citalopram was well tolerated 
and at the end of the trial 86% of the original participants 
chose to continue treatment.75
These promising data led to further research, including 
randomized, placebo-controlled trials. One study involved 
100 postmenopausal women who were randomized into 
four groups: citalopram, placebo, citalopram and hormone 
therapy, or placebo and hormone therapy. Mean hot flash 
scores improved in all groups with reductions of 37%, 13%, 
50%, and 14%, respectively. Thus, this study supported the 
previous findings that citalopram was successful in relieving 
hot flashes and found that its beneficial effect was increased 
with adjuvant hormonal therapy. Of note, women with a his-
tory of breast cancer, venous thromboembolism, or women 
who did not want to take hormone therapy were excluded 
from the hormone therapy treatment groups.76 A more recent 
randomized controlled trial was performed in 254 women 
who were allotted to receive either placebo or citalopram at 
10 mg daily, 20 mg daily, or 30 mg daily. Hot flash frequency 
decreased by 20%, 46%, 43%, 50%, respectively.77
CYP2D6
Although newer antidepressants have shown to be a promising 
therapy for hot flashes, some of them may be contraindicated 
in breast cancer patients. Tamoxifen is a selective estrogen 
receptor modulator that is widely used for both the treatment 
and prevention of breast cancer. Tamoxifen is metabolized 
into its active metabolite, endoxifen, by a cytochrome p450 
enzyme CYP2D6.78 Some newer antidepressants, especially 
paroxetine and fluoxetine, can inhibit this enzyme resulting 
in lower levels of endoxifen. Venlafaxine has less of an 
inhibitory effect on plasma levels of endoxifen.79 The effect 
of citalopram on plasma levels of endoxifen is less clear. 
However, the isoenzymes involved in the metabolism of 
citalopram are mainly CYP3A4 and CYP2D6 and thus it is 
not expected that citalopram would have very much of an 
effect on tamoxifen metabolism.75 Given currently available 
information, venlafaxine should, ideally, be selected if 
an antidepressant is chosen to treat a patient receiving 
tamoxifen.
Gabapentin
Gabapentin is structurally related to the neurotransmitter 
γ-aminobutyric acid and is currently used as an anticonvulsant 
and for neuropathic pain. Gabapentin was first recognized as 
a possible treatment for hot flashes in 2000 when Guttuso 
described 6 cases in which gabapentin treatment reduced 
the frequency of hot flashes.80 Based on these data, a pilot 
trial was reported in 2002, which involved 20 women. 
Patients were treated with gabapentin for 4 weeks with 
increasing doses from 300 mg to 900 mg daily. Patients 
taking gabapentin experienced a decrease in hot flash 
frequency of 66%.81
Since this time, multiple randomized controlled trials 
have evaluated the efficacy of gabapentin for the treat-
ment of hot flashes. The first randomized, double-blind, 
placebo-controlled trial, involved 59 postmenopausal women 
who were treated with either 900 mg daily of gabapentin 
or placebo. After 12 weeks of treatment, women receiving 
gabapentin experienced a 45% reduction in hot flash fre-
quency, versus a 29% reduction seen in the placebo group. 
After the 12 week treatment period, there was an open-label 
treatment phase, during which patients increased the dose 
of gabapentin to 2700 mg per day. This higher dose was 
associated with a 54% reduction in hot flash frequency and 
was not associated with increased adverse events.82 Another 
large randomized, double-blind, placebo-controlled trial 
involved 420 women with breast cancer and assigned them 
to receive placebo, gabapentin 300 mg daily or 900 mg daily. International Journal of Women’s Health 2010:2 submit your manuscript | www.dovepress.com
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After 4 weeks, the reduction in hot flash severity scores was 
21%, 33%, 49%, respectively. Overall, gabapentin at 900 mg 
daily was associated with a greater hot flash reduction than 
300 mg daily.83
The efficacy of gabapentin was then compared to estrogen 
and placebo in a third randomized controlled trial. This study 
involved 60 postmenopausal women who received either 
625 µg/day of conjugated estrogens, placebo, or gabapen-
tin titrated to 2400 mg/day. After 12 weeks, the hot flash 
composite score reduced by 72% in the estrogen group, 71% 
in the gabapentin group, and 54% in the placebo group.84 
While this study supports a higher dose of gabapentin, the 
treatment groups only involved 20 women and the overall 
improvement was only 20% more than placebo.73 Therefore, 
the recommended dose for treatment of hot flashes is 
currently 900 mg/day.
Pregabalin
Pregabalin is a newer generation compound with a 
mechanism of action similar to gabapentin. Therefore, it 
was hypothesized that it would also be effective against 
hot flashes. This hypothesis was first tested in a pilot study 
involving 6 patients and demonstrated a median reduction 
in hot flashes of 65% in patients taking pregabalin.85 To 
further investigate these positive findings, a randomized, 
double-blind, placebo-controlled trial was performed. 
163 women either received pregabalin at a target dose of 
75 mg twice a day, 150 mg twice a day, or placebo. After 
6 weeks, hot flash scores decreased by 65%, 71%, and 50%, 
respectively. Toxicities included weight gain, sleepiness, 
dizziness, and cognitive troubles that were more significant 
with the higher dose. Nonetheless the dropout rates for 
toxicity were similar in all three groups, which implies that 
these symptoms were mild.86
Complementary and  
alternative therapies
Phytoestrogens
It has been reported that only 10%–20% of women in Asia 
experience hot flashes. This is significantly less than the 
80%–90% prevalence in the United States.87,88 One theory for 
this difference is the predominance of soybeans and soy-based 
dishes in the Asian diet. Soy is a potent source of phytoestro-
gens, which are naturally occurring compounds with both 
estrogenic and anti-estrogenic properties.89 Phytoestrogens 
can be classified into two main classes: isoflavones and 
lignans. Recently, there has been interest in phytoestrogens 
as treatment for hot flashes.
Soy is a common source of isoflavones and has been studied 
as a treatment for hot flashes. In a randomized, double-blind, 
placebo-controlled trial, 91 perimenopausal women were 
given isoflavone-rich soy protein, isoflavone-poor soy 
protein, or whey protein. After 12 weeks there were no 
significant differences in hot flash frequency or severity 
between the 3 groups.90 A recent meta-analysis reviewed 11 
trials of soy isoflavone extracts for treatment of hot flashes 
and overall the data was not positive.54 Soy phytoestrogens 
were also explored for the treatment of hot flashes in breast 
cancer patients. One double-blind clinical trial involved 177 
breast cancer survivors who received either soy tablets or 
placebo. After 4 weeks there was no difference in hot flash 
frequency between groups. This trial had a double-blind 
cross-over component. The cross-over study results were also 
negative. Interestingly, at the end of the trial more women 
chose to continue placebo than the soy product.91 Further 
clinical trials of soy phytoestrogens in breast cancer patients 
also showed similar negative results.92
Isoflavones can also be derived from red clover. A large 
clinical trial tested two dietary supplements derived from 
red clover, promensil and rimostil. 252 menopausal women 
were randomized to receive promensil, rimostil, or placebo. 
After 12 weeks there was no clinically important reduction 
in hot flash frequency in either treatment group.93 A recent 
meta-analysis reviewed 6 trials of red clover for the treatment 
of hot flashes with similar negative results.54
Lignan is another form of phytoestrogen, which is found 
in whole grains, legumes, vegetables, and in especially high 
concentrations in flaxseed.89 Lignan is structurally similar to 
estradiol and tamoxifen and has possible tumor inhibitory 
effects on estrogen positive breast cancer.94 An increasing 
amount of research is currently being undertaken on 
flaxseed as a treatment for hot flashes. A pilot trial involved 
30 women who received 40 g of crushed flaxseed daily. After 
6 weeks of therapy there was a 50% reduction in hot flash 
frequency.95 A double-blind, randomized controlled trial 
included 87 women who ingested either muffins with 25 g 
of flaxseed, 25 g grams of soy, or wheat. After 16 weeks, 
neither flaxseed or soy flour affected hot flash frequency 
but there was a significant reduction in severity of hot 
flashes for those consuming the flaxseed muffins.96 Another 
double-blind, placebo-controlled, randomized clinical trial 
of flaxseed has completed its accrual goals and, hopefully, 
should be reported by 2011. A recent Cochrane meta-
analysis summarizes the findings of 30 clinical trials, which 
investigated the effect of various forms of phytoestrogens on 
hot flashes. According to this meta-analysis there is currently  International Journal of Women’s Health 2010:2 submit your manuscript | www.dovepress.com
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no evidence that phytoestrogen supplementation reduces 
either the frequency or severity of hot flashes.97 However, 
a meta-analysis of isoflavone therapy did report a slight to 
modest reduction in the number of hot flashes experienced 
by menopausal women.98 Therefore, although at this time 
phytoestrogens are not recommended for the treatment of 
hot flashes, it is quite feasible that with further research some 
phytoestrogen products will be demonstrated to be effective 
in the alleviation of hot flashes.
Black cohosh
Black cohosh, also known as Cimicifuga racemosa, is 
a plant native to the eastern United States and Canada. 
American Indians originally used it as a remedy for menstrual 
and menopausal conditions.99 A meta-analysis reviewed 
4 randomized controlled trials of black cohosh and this 
report stated that 3 of the 4 trials found black cohosh to be 
beneficial for the treatment of hot flashes.92 However, most 
of these trials were from the 1980s. More recent clinical tri-
als have not found any beneficial effect from black cohosh. 
In 2006, a double-blind, randomized cross-over clinical trial 
was undertaken where patients received black cohosh for 
4 weeks and then placebo or placebo and then black cohosh 
treatment. The trial failed to show any evidence that black 
cohosh was more effective at relieving hot flashes than 
placebo.100 A recent randomized, double-blind clinical trial 
from 2009 compared black cohosh, red clover and placebo 
for the relief of hot flashes. 89 women were randomized to 
receive black cohosh 128 mg/day, red clover 120 mg/day, or 
hormone therapy (625 µg estrogen and 2.5 mg progestin). At 
the end of 12 months the reduction in vasomotor symptoms 
was 34% in the black cohosh group, 57% in the red clover 
group, 63% in the placebo group, and 94% in the hormone 
therapy group. Thus, neither red clover nor black cohosh 
significantly reduced hot flashes.101 In addition, there is some 
concern regarding possible adverse effects of black cohosh on 
the liver and its overall long-term safety.19,92 Therefore, black 
cohosh is not recommended as a treatment for hot flashes
vitamin e
Vitamin E was first recognized as a possible treatment for hot 
flashes in the 1940s.102,103 The first randomized, cross-over, 
clinical trial took place in 1998 when 120 women received 
4 weeks of vitamin E (800 IU daily) then 4 weeks of placebo 
or vice versa. On crossover analysis, vitamin E was associ-
ated with a reduction of hot flashes of about 1 hot flash per 
day. However, at the end of the study patients did not prefer 
vitamin E over the placebo.104 In recent years there has been 
concern about the carcinogenicity of vitamin E, however there 
is reported evidence that vitamin E does not increase cancer 
risk.105 Therefore, at this time vitamin E cannot be strongly 
recommended as an effective treatment for hot flashes.
DHeA
Dehydroepiandrosterone (DHEA) is proandrogen pro-
duced by the adrenal glands and liver. It is proposed that 
DHEA levels decrease as women age and supplementing 
DHEA may have some effect in treating menopausal symp-
toms.106,107 A small trial in 2000 studied 6 months of DHEA 
supplementation in postmenopausal women and reported 
a significant decrease in vasomotor symptoms.108 A more 
recent pilot study was performed in 22 women and found a 
decrease in mean hot flash scores of 50% and an improvement 
in quality of life related to hot flashes after 4 weeks of DHEA 
therapy.106 These positive findings still need to be evaluated 
in a large randomized placebo-controlled trial.
Other herbal remedies
Evening primrose oil (Oenothera biennis) is rich in linoleic 
acid and is extracted from seeds of the evening primrose 
plant.109 A randomized, double-blind, placebo-controlled 
study was undertaken to evaluate the efficacy of evening 
primrose oil in treating hot flushes and found that evening 
primrose oil to have no benefit for hot flash relief.110
Dong quai (Angelica sinensis) is a Chinese herb 
which is traditionally used to treat menopausal symptoms. 
A randomized controlled trial in 71 women demonstrated no 
difference in hot flashes between dong quai treatment and pla-
cebo groups.111 In addition, dong quai has been found to have 
estrogen like activity.112,113 Therefore, not only does dong 
quai lack any established efficacy for treating hot flashes, its 
safety in breast cancer patients remains unclear.
Ginseng (Panax ginseng) is one of the most popular 
herbal supplements sold in the United States. It is often 
used as a restorative agent to treat fatigue or exhaustion.109 
A randomized double-blind trial investigated the effects 
of ginseng extract on the quality of life and physiological 
parameters in women experiencing hot flashes. There was 
no significant difference in vasomotor symptoms between 
the treatment group and a placebo group.114
Wild Yam (Dioscorea villosa) is a natural progesterone 
cream, which contains phytosteroids and has been promoted 
for the treatment of hot flashes.115 However, a double-blind, 
placebo-controlled, cross-over study found no significant 
difference in menopausal symptoms between the treatment 
and placebo group.116International Journal of Women’s Health 2010:2 submit your manuscript | www.dovepress.com
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Currently there is no sound evidence demonstrating that 
evening primrose oil, dong quai, ginseng, or wild yam are 
effective in treating hot flashes and therefore should not be 
used as a therapy for vasomotor symptoms.
Mind-body and behavior therapies
Behavioral modifications
Despite the large variety of pharmacological options for the 
treatment of hot flashes, the North American Menopause 
Society recommends lifestyle changes as the first line therapy 
for patients suffering from mild vasomotor symptoms.117 One 
key lifestyle modification involves keeping the core body 
temperature cool using techniques such as loose clothing, 
sipping cold drinks, avoiding spicy food, and keeping a lower 
room temperature.117,118
exercise
An increasing amount of research is being undertaken on the 
effect of exercise on hot flashes. However, there is currently 
no evidence from randomized controlled trials that show that 
exercise is an effective treatment for hot flashes.119,120
Yoga
Yoga is a combination of exercise and meditation, which 
involves gentle stretching and breath control. Recently yoga 
has been studied as a treatment for menopausal symptoms. One 
large clinical trial involved 108 women who received either 
8 weeks of yoga or regular physical exercises. The symptom 
assessment was made using the Greene Climacteric Scale 
and it was reported that there was a decrease in vasomotor 
symptoms in the group involved in the yoga program.121
A recent randomized pilot trial studied the use of yoga for hot 
flash treatment in breast cancer survivors. This study involved 
37 breast cancer survivors who received either 8 weeks of yoga 
or were on a wait-list control. After the treatment, women who 
were involved in the yoga program showed improvements in 
hot flash frequency, severity, and total scores.122 However, the 
reduction in hot flash score was only 31%, which could be 
attributed to placebo response. A recent review of the literature 
on this topic concluded that current evidence does not support 
the use of yoga for menopausal symptoms.123 Further research 
is needed to better investigate this area.
Relaxation training
Relaxation techniques are methods of reducing stress and 
anxiety. Many different forms of relaxation have been 
investigated for the treatment of menopausal symptoms. One 
form of relaxation training is paced breathing, which involves 
slow, rhythmic, diaphragmatic breathing. Small randomized 
trials have investigated paced breathing for hot flashes and 
claimed positive results.124,125 These encouraging results led 
to a randomized phase II study to evaluate the efficacy of 
paced breathing for hot flashes; the results from this trial, 
which has completed its accrual goal, are pending.
The efficacy of relaxation as a treatment for hot flashes 
has also been studied in breast cancer patients. A recent 
randomized controlled trial investigating relaxation involved 
150 women with a history of breast cancer who received 
either a single relaxation training session with instruction to 
use practice tapes daily for one month versus no intervention. 
After one month, the incidence and severity of hot flashes 
significantly declined in the treatment group. However, there 
was no difference between groups at 3 months.126
Mindfulness-based stress reduction (MBSR) is another 
form of trained relaxation. It is a program that teaches 
mindfulness meditation and yoga as a way to cope with 
stress.127 A pilot study investigated the effect of an MBSR 
program on hot flashes. This study included 15 women who 
attended the 8-week MBSR program. At the end of the 11-week 
assessment period, the hot flash severity decreased by 40%.128 
However, this may result from a placebo effect alone.
A recent review of the literature on the efficacy of relaxation 
techniques on hot flash control concluded that most trials 
had positive results. However, the trials were designed with 
small sample sizes and included a variety of interventions and 
outcome measures. Therefore, more large well-designed ran-
domized controlled trials are needed to further evaluate the efficacy 
of these various forms of relaxation on hot flash control.129
Hypnosis
Hypnosis is a mind-body therapy that uses mental imagery to 
induce a state of deep relaxation and heightened focus. Hypnosis 
has been found to be useful in the management of multiple medi-
cal conditions including pain, anxiety, and insomnia.130–133 It also 
has been reported to reduce anxiety and distress in breast cancer 
patients.134–136 Hot flashes are often associated with anxiety and 
stress. Therefore, it has been proposed that hypnosis may act to 
reduce hot flashes. This theory was evaluated by a pilot trial of 
hypnosis in breast cancer patients suffering from hot flashes. 
The trial reported positive results, with a 59% decrease in total 
daily hot flashes from baseline.137 A larger trial of hypnosis for 
the treatment of hot flashes was performed in 51 breast cancer 
survivors and found similar results with hot flashes decreasing 
by 68% in the hypnosis group.138 These preliminary data are 
encouraging and larger randomized clinical trials of hypnosis 
for hot flashes are currently underway. International Journal of Women’s Health 2010:2 submit your manuscript | www.dovepress.com
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Acupuncture
Acupuncture involves the use of thin needles inserted into 
specific points of the body. It has been used in Asia for thou-
sands of years and has recently gained popularity in the west 
as a treatment for multiple conditions. Over the past decade 
many trials have explored the effect of acupuncture on hot 
flash symptoms. A recent review of the literature included 
trials of acupuncture for the treatment of hot flashes that were 
performed prior to July 2008. This review included six trials that 
compared acupuncture treatment to sham or placebo acupunc-
ture, five of those trials found no significant difference between 
groups.139 Another recent review explored the literature regard-
ing the effect of acupuncture on hot flashes in breast cancer 
patients. This review found three randomized controlled trials, 
which compared the effects of acupuncture to sham procedure. 
Two of these trials failed to show any positive results from the 
acupuncture.140 Therefore, to date, there is no evidence that 
acupuncture is an effective treatment for hot flashes.
Stellate sanglion block
Stellate ganglion block (SGB) is commonly used to treat a vari-
ety of pain syndromes and vascular insufficiency.141 The positive 
effect of SGB on hot flashes was first reported in a case report 
by Lipov and colleagues. The series involved 6 women, all of 
whom experienced a significant reduction in hot flashes after 
the SGB.142 In response to these encouraging results the same 
researchers performed a pilot study involving 13 women with 
a history of breast cancer. Again, it was reported that a SBG 
significantly reduced the frequency and severity of hot flashes. 
In addition, there were no significant adverse events related 
to the procedure.143 A more recent pilot trial was undertaken 
to evaluate the efficacy of SGB for hot flashes and involved 
9 women with a history of breast cancer. The results of this pilot 
trial supported those reported by Lipov and colleagues.144
The mechanism by which SGB might reduce hot flashes 
is unclear. However, Lipov and colleagues proposed that 
the stellate ganglion has links with the areas of the central 
nervous system that control body temperature. A SGB may 
interrupt these connections and allow the body temperature 
regulating mechanisms to reset.145 Large randomized 
controlled trials are needed to further clarify the use of SGB 
for hot flashes, and are currently underway.
Conclusion
Hot flashes are one of the most common and distressing 
symptoms associated with menopause. Hot flashes are 
especially problematic because the most well recognized 
effective treatment, estrogen, is often contraindicated. 
This dilemma has lead to an extensive amount of research 
exploring different therapeutic options for the treatment of hot 
flashes. Currently, multiple safe and efficacious non-hormonal 
modalities exist. As the mechanism of hot flashes is further 
elucidated and research in this area grows, newer therapies 
for hot flashes will most likely become established.
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